Almirall Signs an In-License Agreement with 23andMe for Multiple Inflammatory Diseases
Shots:
- 23andMe has out-license its bispecific mAb targeted to block three members of the IL-36 cytokine subfamily & will leverage Almirall’s expertise in medical dermatology & accelerating the development the preclinical program
- Almirall to get exclusive WW rights to develop and commercialize the mAbs and will also be responsible for clinical studies. The focus of the agreement is to strengthen ALmirall’s early-stage research portfolio
- IL-36 is an IL-1 cytokine family targeted for associated with multiple inflammatory diseases, including various dermatological conditions
Click here to read full press release/ article | Ref: Almirall | Image: Twitter